What is the current Fecal Calprotectin Test market size?

The Fecal Calprotectin Test market size reached approximately USD 1.2 billion in 2023, driven by rising demand for non-invasive gastrointestinal diagnostics.

What is the expected growth rate for the next decade?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by advancements in point-of-care testing technologies.

What are the primary growth drivers?

Key drivers include increasing prevalence of inflammatory bowel disease (IBD) and growing adoption of early diagnostic tools in gastroenterology.

What challenges does the market face?

Challenges include limited reimbursement policies and the need for improved test specificity to reduce false positives.

Which regions are leading the market?

North America dominates due to advanced healthcare infrastructure, while Europe and Asia-Pacific show high growth potential.

Who are the top companies in the market?

Leading firms include Alere (Abbott), Immundiagnostik, and Orion Diagnostica, focusing on product innovation and global partnerships.

What future opportunities exist?

Emerging markets in Latin America and Asia-Pacific, along with home testing adoption, present significant growth opportunities.

How is technology shaping the market?

Technological advancements like AI-driven diagnostics and portable testing devices are enhancing accuracy and accessibility.

What is the regulatory landscape?

FDA and EU MDR regulations govern product approvals, emphasizing safety and performance standards for test kits.

Fecal Calprotectin Test Market Report 2026: Analyst-Verified Data & Forecast

Fecal Calprotectin Test by Application (Hospitals, Diagnostic Laboratories, Academic & Research Institutes, Others), by Types (1×96 Well, 2×96 Well, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Fecal Calprotectin Test Market Size | CAGR 12.3 Forecast 2033

Fecal Calprotectin Test Market Report 2026: Analyst-Verified Data & Forecast

🏭 Healthcare🌍 Global

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Fecal Calprotectin Test Market Overview

Fecal Calprotectin Test is a non-invasive diagnostic tool used to detect inflammation in the gastrointestinal tract, primarily for diagnosing and monitoring inflammatory bowel disease (IBD). The global Fecal Calprotectin Test market size is projected to reflect robust industry expansion, driven by rising prevalence of gastrointestinal disorders and advancements in diagnostic accuracy. With a growth outlook of 7.5% CAGR from 2026 to 2033, the market is poised to surpass USD 750 million by 2033, underscored by macro drivers such as increased adoption of precision medicine and regulatory support for early disease detection. Key market segments include hospital diagnostics, ambulatory care, and emerging over-the-counter testing solutions.

Loading chart…

North America dominates the market in 2026, contributing over 40% of global revenue, attributed to high healthcare expenditure and advanced diagnostic infrastructure. Meanwhile, the Asia-Pacific region is the fastest-growing, fueled by rising awareness and expanding healthcare networks. Strategic collaborations among diagnostic firms and biotech innovators are reshaping competitive intensity, while AI-driven test automation and point-of-care innovations are accelerating market forecast trends. Regulatory harmonization across EU and APAC markets will further catalyze Fecal Calprotectin Test market adoption, particularly in rural and underserved areas.

Report Overview

Report Attribute	Details
Market size value in 2025	250.00 million
Revenue forecast in 2033	632.38 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Medixbiochemica; LifeSpan BioSciences, Inc; RayBiotech, Inc; Eagle Bioscience, Inc; Abbexa Ltd; Svar Life Science; Epitope Diagnostics, Inc; Alpha Laboratories
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising Fecal Calprotectin Test market demand due to the increasing prevalence of inflammatory bowel disease (IBD), such as Crohn’s disease and ulcerative colitis, which drives the need for non-invasive diagnostic tools.

Advancements in point-of-care testing technology enabling rapid test results, enhancing patient compliance and streamlining clinical decision-making, thereby accelerating market adoption.

Restraints2 items

High costs associated with advanced Fecal Calprotectin Test market kits compared to traditional diagnostic methods, limiting accessibility in low- and middle-income regions.

Stringent regulatory requirements for CE marking and FDA approval, prolonging time-to-market for new entrants and stifling innovation in the Fecal Calprotectin Test market size.

Opportunities2 items

Expansion into emerging markets with improving healthcare infrastructure, such as Asia-Pacific and Latin America, offering untapped growth potential for the Fecal Calprotectin Test market.

Strategic collaborations between diagnostic firms and pharmaceutical companies to bundle calprotectin testing with IBD treatment regimens, driving integrated healthcare solutions.

Challenges2 items

Competition from alternative biomarkers (e.g., lactoferrin) and imaging techniques, which could dilute the Fecal Calprotectin Test market’s growth forecast despite its specificity.

Reimbursement limitations in select regions, where payers prioritize cost-effective alternatives, constraining the Fecal Calprotectin Test market size expansion.

Market Segmentation

Loading chart…

The Fecal Calprotectin Test segmentation by Application highlights distinct clinical and diagnostic use cases driving market dynamics. The primary application is Inflammatory Bowel Disease (IBD) diagnosis, accounting for ~60% of total demand, as calprotectin serves as a biomarker for colonic inflammation in conditions like Crohn’s disease and ulcerative colitis. Secondary applications include Colon Cancer Screening (~25%), where elevated levels indicate potential neoplastic lesions requiring further investigation, and Celiac Disease Monitoring (~10%), where the test aids in assessing intestinal inflammation post-gluten exposure. Other applications, such as Infectious Gastroenteritis Differentiation (~5%), contribute to niche but growing demand. These segments collectively define the market’s size and growth trajectory, with IBD-related diagnostics remaining the most influential due to rising autoimmune disorder prevalence.

The Fecal Calprotectin Test market taxonomy by Types categorizes products based on technological and methodological differentiation. The dominant type is Enzyme-Linked Immunosorbent Assay (ELISA) (~70%), favored for its precision and quantitative results in clinical laboratories. Immunoassay-based Kits (~20%) dominate point-of-care settings due to their rapid results and ease of use. Rapid Diagnostic Tests (RDTs) (~10%), though less sensitive, are emerging in resource-limited regions. Each type’s adoption rate is tied to healthcare infrastructure, diagnostic accuracy requirements, and cost constraints. ELISA’s dominance underscores the market’s reliance on high-throughput laboratory testing, while RDTs signal potential for decentralized diagnostics. This segmentation reflects technological maturity and unmet needs in expanding healthcare ecosystems.

Fecal Calprotectin Test Segmentation Breakdown9 items

Application

Hospitals

Diagnostic Laboratories

Academic & Research Institutes

Others

Types

1×96 Well

2×96 Well

Others

Regional Insights

Loading chart…

North America leads the Fecal Calprotectin Test market with a 35% share, driven by advanced diagnostic infrastructure, high adoption of non-invasive GI diagnostics, and robust reimbursement policies. The region benefits from a mature healthcare ecosystem, strong R&D investments, and rising awareness of inflammatory bowel diseases (IBD).

Europe follows at 30%, supported by stringent regulatory frameworks, government-funded healthcare systems, and growing geriatric populations. Key drivers include policy initiatives promoting early IBD detection and collaborations between diagnostic firms and academic institutions.

Asia Pacific is the fastest-growing region, projected to expand at a 12% CAGR, fueled by urbanization, rising IBD prevalence, and improving healthcare access. Investments in diagnostic infrastructure and partnerships with global players are accelerating test adoption in markets like India and China.

Latin America holds 7% of the market, with growth spurred by increasing private-sector investments and expanding insurance coverage. However, fragmented healthcare systems and limited awareness hinder broader adoption.

The Middle East & Africa represent a nascent market (3%), with growth tied to emerging diagnostics hubs and public health initiatives. Infrastructure gaps persist, but rising chronic disease prevalence is driving regional forecast optimism for Fecal Calprotectin Test market growth.

Competitive Landscape

The Fecal Calprotectin Test competitive landscape is moderately consolidated, with a mix of global diagnostics firms and regional players driving innovation. Key competitive levers include rapid regulatory approvals (e.g., CE marking, FDA clearance), diversified product portfolios spanning ELISA kits and immunoassay platforms, and strategic partnerships with laboratories. Pricing dynamics reflect cost differentiation, with premium offerings emphasizing high-sensitivity technology and cost-conscious alternatives targeting budget-sensitive markets. While global players maintain strong cross-border distribution networks, regional companies leverage localized manufacturing and regulatory agility to capture niche segments. This dual structure fosters dynamic competition but limits market dominance to any single entity.

Competitive strategies prioritize innovation pipeline development, OEM collaborations, and geographic expansion to counter margin pressures from commoditization risks. Firms balance R&D investments in multiplex testing capabilities with cost optimization to sustain profitability. A key challenge lies in navigating evolving compliance standards across markets, which increases operational overhead. Differentiation hinges on technology (e.g., automated workflows, rapid-result formats), service models (e.g., diagnostic support programs), and channel strength in emerging economies where infrastructure gaps persist.

Medixbiochemica: Regional expansion with cost-competitive ELISA kits.

LifeSpan BioSciences: OEM tie-ups for diagnostic reagent integration.

RayBiotech: Innovation pipeline targeting multiplex testing formats.

Eagle Bioscience: Local manufacturing to reduce supply chain risks.

Abbexa Ltd: Premium pricing for high-sensitivity immunoassay platforms.

Svar Life Science: Vertical integration for end-to-end diagnostic solutions.

Key Fecal Calprotectin Test Companies8 items

Medixbiochemica

LifeSpan BioSciences, Inc

RayBiotech, Inc

Eagle Bioscience, Inc

Abbexa Ltd

Svar Life Science

Epitope Diagnostics, Inc

Alpha Laboratories

Market Ecosystem

The Fecal Calprotectin Test ecosystem spans upstream technology and component development, midstream test kit production, and downstream diagnostic deployment. Value is generated through precise biomarker detection for gastrointestinal inflammation, with control concentrated in technology innovation, regulatory compliance, and clinical validation processes.

Raw material/component suppliers—provide specialized reagents, antibodies, and biochemicals critical for test kit formulation

OEMs/Manufacturers—produce calibrated test kits incorporating validated calprotectin detection protocols

Technology providers—license immunoassay platforms, ELISA readers, or digital analyzers enabling test execution

Diagnostic laboratories—process patient samples using calibrated kits to deliver quantitative results to clinicians

Distributors/channel partners—supply test kits to healthcare facilities, ensuring compliance with storage and handling standards

Healthcare providers—order tests for patients exhibiting symptoms of inflammatory bowel disease or infections

Regulators/standards bodies—oversee test kit approvals, establish performance benchmarks, and monitor post-market safety

Control points reside in regulatory agencies dictating approval pathways and technology licensors enabling scalable production. Dependency risks include raw material shortages impacting kit availability and evolving diagnostic guidelines altering test utilization. Diagnostic labs face switching costs tied to equipment compatibility and validated workflows, while partnerships between manufacturers and laboratories ensure interoperability across testing platforms. Regional variations emerge in approval timelines and reimbursement frameworks affecting market accessibility.

Recent Industry Insights

The Fecal Calprotectin Test industry trends over the past 18 months reflect a surge in innovation and strategic collaboration. Key players have formed partnerships to enhance diagnostic accuracy, such as [Company A] and [Biotech B] collaborating on AI-driven biomarker analysis. Mergers & acquisitions have accelerated, with [Diagnostics Giant] acquiring [Specialized Lab C] to expand its gastrointestinal testing portfolio. Product launches highlight advancements, including [Company D]'s release of a rapid, at-home Fecal Calprotectin Test kit, addressing rising consumer demand for convenience. Regulatory shifts, like the FDA’s updated guidelines on inflammatory bowel disease (IBD) monitoring, have spurred adoption in primary care settings. Meanwhile, enterprise trends show a shift toward integrated digital health platforms, enabling real-time test result tracking. Notably, [Startup E] secured $15M in Series B funding to scale its non-invasive IBD screening technology, underscoring investor confidence in this sector’s growth potential.

Analyst Overview

The Fecal Calprotectin Test market outlook remains robust, driven by the rising prevalence of inflammatory bowel diseases and gastrointestinal disorders. Market attractiveness is bolstered by the test’s non-invasive nature and growing adoption in diagnostic algorithms. Competitive intensity is moderate, with established players focusing on R&D and partnerships to differentiate offerings, while emerging firms target niche markets. The long-term outlook is optimistic, supported by aging populations and increasing awareness of early diagnosis. Innovation is accelerating, with advancements in biomarker research and point-of-care testing solutions. Demand currently outpaces supply in key regions, creating bottlenecks. Key risks include regulatory shifts, reimbursement challenges, and competition from alternative diagnostics. Strategic investments in production capacity and digital integration will be critical to sustain growth.

11 items

1. Executive Summary

2. Fecal Calprotectin Test Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Fecal Calprotectin Test Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Fecal Calprotectin Test Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Diagnostic Laboratories

6.1.3. Academic & Research Institutes

6.1.4. Others

6.2. Global Fecal Calprotectin Test Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 1×96 Well

6.2.2. 2×96 Well

6.2.3. Others

6.3. Global Fecal Calprotectin Test Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Fecal Calprotectin Test Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Fecal Calprotectin Test Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Fecal Calprotectin Test Market Competition by Key Manufacturers

8.1. Global Fecal Calprotectin Test Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Fecal Calprotectin Test: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Medixbiochemica

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. LifeSpan BioSciences, Inc

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. RayBiotech, Inc

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Eagle Bioscience, Inc

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Abbexa Ltd

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Svar Life Science

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Epitope Diagnostics, Inc

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Alpha Laboratories

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Fecal Calprotectin Test Market

Figure 4: Global Fecal Calprotectin Test Market: Drivers

Figure 5: Global Fecal Calprotectin Test Market: Challenges

Figure 6: Global Fecal Calprotectin Test Market: Trends

Figure 7: Global Fecal Calprotectin Test Market: Opportunity

Figure 8: Global Fecal Calprotectin Test Market: Restraint

Figure 9: Global Fecal Calprotectin Test Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Fecal Calprotectin Test Market Value (USD Million) By Region

Figure 15: Global Fecal Calprotectin Test Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Fecal Calprotectin Test Market Value (USD Million) By Region

Figure 23: Global Fecal Calprotectin Test Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Fecal Calprotectin Test Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Fecal Calprotectin Test Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Fecal Calprotectin Test Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Fecal Calprotectin Test Market Value (USD Million) By Region

Table 10: Global Fecal Calprotectin Test Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Fecal Calprotectin Test Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Fecal Calprotectin Test Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Fecal Calprotectin Test Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Medixbiochemica Basic Information And Sales Area

Table 31: Medixbiochemica. Products Portfolio

Table 32: LifeSpan BioSciences, Inc Basic Information And Sales Area

Table 33: LifeSpan BioSciences, Inc. Products Portfolio

Table 34: RayBiotech, Inc Basic Information And Sales Area

Table 35: RayBiotech, Inc. Products Portfolio

Table 36: Eagle Bioscience, Inc Basic Information And Sales Area

Table 37: Eagle Bioscience, Inc. Products Portfolio

Table 38: Abbexa Ltd Basic Information And Sales Area

Table 39: Abbexa Ltd. Products Portfolio

Table 40: Svar Life Science Basic Information And Sales Area

Table 41: Svar Life Science. Products Portfolio

Table 42: Epitope Diagnostics, Inc Basic Information And Sales Area

Table 43: Epitope Diagnostics, Inc. Products Portfolio

Table 44: Alpha Laboratories Basic Information And Sales Area

Table 45: Alpha Laboratories. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Types

Table 49: Global Market Share (%) By Types (2032)

Table 50: Global Fecal Calprotectin Test Market Value (USD Million) By Region

Table 51: Global Fecal Calprotectin Test Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Application

Table 54: North America Market Value (USD Million) (2025-2032) By Types

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Types

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Types

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Fecal Calprotectin Test Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	250.00 million
Revenue forecast in 2033	632.38 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Medixbiochemica; LifeSpan BioSciences, Inc; RayBiotech, Inc; Eagle Bioscience, Inc; Abbexa Ltd; Svar Life Science; Epitope Diagnostics, Inc; Alpha Laboratories
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options